Evidence map›Paper›PMID 41364803›Full record

ArticleJMIR research protocols2025

Effectiveness of a Cardiovascular Management System on Triple Risk Factor Control in High-Risk Older Adults: Protocol for a Randomized Controlled Trial.

Yan Wang, Lei Su, Jingyi Xiao, Xiaoying He, Hua Hong, Lin Xu

Abstract readClinical Trial Protocol
In one paragraph

Article in JMIR research protocols, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yan WangCentre of Health Management, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.ORCID 0009-0000-0458-5120
Lei SuDepartment of Geriatrics, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.ORCID 0000-0002-5569-1991
Jingyi XiaoCentre of Health Management, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.ORCID 0009-0003-0812-2678
Xiaoying HeCentre of Health Management, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.ORCID 0000-0002-8195-8725
Hua Hong *Centre of Health Management, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.ORCID 0000-0002-6237-074X
Lin Xu *Department of Applied Health Sciences, University of Birmingham, Edgbaston, Birmingham, England, B15 2TT, United Kingdom, 86 20-87335523.ORCID 0000-0002-0537-922X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cardiovascular disease (CVD) remains a leading cause of morbidity and mortality in China. Although the National Basic Public Health Services Program provides annual health checkups for older adults, postscreening management of CVD risk factors such as hypertension, dyslipidemia, and diabetes is often inadequate. The CardioCare system is a digital cardiovascular management platform that integrates risk prediction, personalized health interventions, and continuous engagement to address these gaps. Objective: This trial aims to evaluate the effectiveness of the CardioCare system in improving triple risk factor control (simultaneous control of blood pressure, lipids, and glycemia) at 12 months among high-risk adults. Secondary objectives include assessing changes in estimated 10-year CVD risk, individual clinical parameters, medication adherence, lifestyle modification, system engagement, usability, satisfaction, and cost-effectiveness. Methods: This is a single-center, parallel-group, superiority randomized controlled trial with a 1:1 allocation ratio. A total of 300 adults aged ≥50 years with an estimated 10-year CVD risk of >10% and no previous CVD diagnosis will be recruited from the Health Management Center of the First Affiliated Hospital of Sun Yat-sen University in Guangzhou, China. Participants will be randomized to receive either the CardioCare system intervention or minimal usual care for 12 months. The intervention includes risk stratification and communication, weekly personalized SMS text messages or WeChat messages, and cardiologist oversight. The primary outcome is the proportion of participants achieving triple risk factor control at 12 months. Secondary outcomes include clinical, behavioral, usability, and economic measures. Analyses will follow the intention-to-treat principle, with multiple imputation for missing data. Results: This trial was funded on October 28, 2024. Recruitment is scheduled to begin in January 2026 and conclude in April 2026, with follow-up completed by June 2027. Data analysis will commence in mid-2027, and the main findings are expected to be published by the end of 2027. As of manuscript submission, recruitment has not yet started. Conclusions: This trial will provide robust evidence on the clinical effectiveness and cost-effectiveness of the CardioCare system in managing multiple cardiovascular risk factors among high-risk adults. The findings will inform the potential for scaling this intervention within health checkup centers and integrating it into national chronic disease management strategies.

Indexed as

Cardiovascular DiseasesAgedChinaCost-Benefit AnalysisEquivalence Trials as TopicFemaleHeart Disease Risk FactorsHumansHypertensionMaleMiddle AgedRandomized Controlled Trials as TopicRisk Factorscardiovascular diseasesdigital healthmedication adherencerandomized controlled trialrisk factor control

Identifiers

PMID41364803
PMCPMC12688048

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.